期刊文献+

多剂口服甲磺酸加替沙星片药代动力学研究

A study on pharmacokinetics of multi - Dose of oral gatifloxacin mehanesulfanae tablets
下载PDF
导出
摘要 目的:在中国健康成年志愿者中进行多剂口服甲磺酸加替沙星片的药代动力学研究.方法:根据GCP原则设计试验方案.选择10名18~40岁健康成人男性,口服甲磺酸加替沙星片每次400mg,每日1次,连续10日.首次给药和第10日给药前及给药后0.083、0.25、0.5、0.75、1.0、1.5、2.0、3.0、4.0、6.0、8.0、12.0、24.0h分别取血;此外每日测定谷浓度和峰浓度.应用高效液相色谱法(HPLC)测定血药浓度,采用3P97软件拟合药代动力学参数.结果:受试者口服甲磺酸加替沙星片,体内过程为二房室模型.连续给药10日后AUC0-∞、AUC0-τ值比首次给药显著增加,但第10日给药后AUC0-τ与首次给药后AUC0-∞差异无统计学意义;其余参数Cmax、T1/2β、Vd等差异亦无统计学意义.平均稳态血药浓度Cav为0.844±0.180 mg·L-1,稳态血药浓度-时间曲线下面积AUCss为26.165±4.530mg·h·L-1,累积比为1.354±0.867,波动系数1.685±0.158.受试者给药期间未出现严重不良反应.结论:口服甲磺酸加替沙星片,每次400mg,每日1次的给药方案,在人体内可达到有效血浆浓度,且连续给药10日体内未见蓄积.该方案适宜在临床推广应用.
出处 《中国药物应用与监测》 CAS 2003年第5期33-36,共4页 Chinese Journal of Drug Application and Monitoring
  • 相关文献

参考文献3

二级参考文献25

  • 1赵树清,王金生.新型氟喹诺酮抗菌剂——AM—1155[J].中国医药情报,1996,2(4):249-252. 被引量:4
  • 2JLM. Oral and iv formulations of gatifoxacin cleared for US. market. Am J Health-Syst Pharm, 2000; 57:204
  • 3Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemther,1995; 36:293
  • 4Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother, 1993;37:1259
  • 5Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian typeⅡ topoisomerase. Antimicro Agents Chemother, 1998;42:2678
  • 6Wakabayshi E, Mitsuhashi S. In vitro antibacterial activitiy of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother, 1994;38:594
  • 7Fukuda H, Hori S, Hiramatsu K. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone- resistants mutants and the norA transformant of staphylococcus aureus. Antimicrob Agents Chemother, 1998;42:1917
  • 8Deguchi T, Yasuda M, Nakano M, et al. Comparision of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. Chemotherapy, 1997;43:239
  • 9Appelbaum PC. Quinolone activity against anaerobes. Drugs, 1999;58 (suppl 2):60
  • 10Ednie LM, Jacobs M, Appelaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother, 1998;42:2459

共引文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部